Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817225) titled 'Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation' on Sept. 8.

Study Type: Observational

Primary Sponsor: Massimo Falconi

Condition: Pancreatic Neuroendocrine Tumor

Intervention: Other: cfDNA molecular profiling

Recruitment Status: Not recruiting

Date of First Enrollment: September 12, 2026

Target Sample Size: 30

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07817225

Published by HT Digital Content Services with permission from Health Daily Digest....